To evaluate the safety and efficacy of gemtuzumab ozogamicin in combination with cytarabine in inducing complete remission in patients with AML and advanced MDS over the age of 60 years.~Patients eligible for treatment will receive the following:~Mylotarg at 6 mg/m2 on day 1 as a 2 hour intravenous infusion~Cytarabine at 100 mg/m2/day as a continuous intravenous infusion daily for 7 days
The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of 60 years.